XERS - Xeris Pharmaceuticals

-

$undefined

N/A

(N/A)

Xeris Pharmaceuticals NasdaqGS:XERS Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Location: 1375 West Fulton Street, Chicago, IL, 60607, United States | Website: https://www.xerispharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.017B

Cash

58.44M

Avg Qtr Burn

-6.677M

Short % of Float

11.57%

Insider Ownership

4.00%

Institutional Own.

54.34%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Recorlev® (levoketoconazole) Details
Rare diseases, Cushing’s syndrome

Approved

Quarterly sales

Phase 2

Update

Pramlintide-Insulin Details
Type 1 diabetes, Diabetes, Type 2 diabetes

Failed

Discontinued

Gvoke RTU Micro™ Details
Hypoglycemia, Type 1 diabetes, Type 2 diabetes

Failed

Discontinued

Failed

Discontinued